Sort   by:  
 Page size 
MetabolomicsInsights into Metabolic Changes Caused by the Trichoderma virens-Maize Root Interaction
The interactions of crops with root-colonizing endophytic microorganisms are highly relevant to agriculture, because endophytes can modify plant resistance to pests and increase crop yields. We investigated the interactions between the host plant Zea mays and the endophytic fungus Trichode...
2021-07-08 | MTBLS1964 | MetaboLights
UnknownPooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Not available
S-EPMC5089162 | biostudies-literature
TranscriptomicsTranscription profiling of S. cerevisiae treated with phenelzine results in a perturbation in the system leads to period doubling
Perturbation of the gated-synchrony system in yeast with phenelzine, an antidepressant drug used in the treatment of affective disorders in humans, leads to a rapid lengthening in the period of the genome-wide transcriptional oscillation. The effect is a concerted, genome-scale change in expression ...
ORGANISM(S): Saccharomyces cerevisiae 
2008-06-16 | E-GEOD-9302 | biostudies-arrayexpress
UnknownFive-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Not available
S-EPMC5795709 | biostudies-literature
TranscriptomicseIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
The amounts of eIF4G and eIF4B were decreased in the vemurafenib-treated sensitive A375 cell line. To find mechanisms behind this decrease, we sought to identify the genes whose expression changes after vemurafenib treatment in A375 cells as compared to Mel624 cells by using microarrays.
ORGANISM(S): Homo sapiens 
2014-12-30 | E-MTAB-2607 | biostudies-arrayexpress
UnknownEfficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Not available
S-EPMC5791828 | biostudies-literature
UnknownEvaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Not available
S-EPMC5070547 | biostudies-literature
TranscriptomicsTranscription profiling of human tumours at baseline and after 21 days of treatment with sorafenib and dacarbazine
Background New approaches are needed to improve prognostic accuracy for treatment response and to explore the complexities of drug effects on human tumours. We developed a strategy of global genomic investigation of sequential tumor biopsies at baseline and 21 days post-treatment, and applied this ...
ORGANISM(S): Homo sapiens 
2010-07-31 | E-TABM-760 | biostudies-arrayexpress
UnknownProgrammed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Not available
S-EPMC5562434 | biostudies-literature
UnknownLonger Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
Not available
S-EPMC6286159 | biostudies-literature
Sort   by:  
 Page size